N/A
Completed N=68
A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
Intestinal FDG Uptake
Source: ClinicalTrials.gov NCT01542541 ↗
Enrolled (actual)
68
Serious AEs
0.0%
Results posted
Jan 2016
Primary outcomePrimary: SUVmax of FDG in Each Colonic Segment — 4.6; 4.3 SUV
Summary
Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SUVmax of FDG in Each Colonic Segment |
4.6; 4.3 | — |
| SECONDARY SUVavg in Each Colonic Segment |
1.6; 1.8 | — |
Eligibility Criteria
Inclusion Criteria
- Patients undergoing clinically-indicated PET-CT scan for non-GI lymphoma
Exclusion Criteria
- Patients with known Inflammatory Bowel Disease
- Patients with known colon cancer
Data sourced from ClinicalTrials.gov (NCT01542541). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.